Revolution Medicines, Inc.
RVMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $11,580 | $35,380 | $29,390 |
| % Growth | -100% | -67.3% | 20.4% | – |
| Cost of Goods Sold | $592,225 | $411,244 | $253,073 | $186,948 |
| Gross Profit | -$592,225 | -$399,664 | -$217,693 | -$157,558 |
| % Margin | – | -3,451.3% | -615.3% | -536.1% |
| R&D Expenses | $592,225 | $423,144 | $253,073 | $186,948 |
| G&A Expenses | $97,299 | $62,021 | $40,586 | $30,450 |
| SG&A Expenses | $97,299 | $62,021 | $40,586 | $30,450 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$592,225 | -$397,644 | -$253,073 | -$186,948 |
| Operating Expenses | $97,299 | $87,521 | $40,586 | $30,450 |
| Operating Income | -$689,524 | -$487,185 | -$258,279 | -$188,008 |
| % Margin | – | -4,207.1% | -730% | -639.7% |
| Other Income/Exp. Net | $88,678 | $47,294 | $9,154 | $917 |
| Pre-Tax Income | -$600,846 | -$439,891 | -$249,125 | -$187,091 |
| Tax Expense | -$753 | -$3,524 | -$420 | $0 |
| Net Income | -$600,093 | -$436,367 | -$248,705 | -$187,091 |
| % Margin | – | -3,768.3% | -703% | -636.6% |
| EPS | -3.58 | -3.86 | -3.08 | -2.47 |
| % Growth | 7.3% | -25.3% | -24.7% | – |
| EPS Diluted | -3.58 | -3.86 | -3.08 | -2.47 |
| Weighted Avg Shares Out | 167,738 | 113,150 | 80,627 | 72,806 |
| Weighted Avg Shares Out Dil | 167,738 | 113,150 | 80,627 | 72,806 |
| Supplemental Information | – | – | – | – |
| Interest Income | $86,883 | $47,482 | $9,154 | $929 |
| Interest Expense | $0 | $0 | $0 | $12 |
| Depreciation & Amortization | $11,824 | $5,010 | $9,656 | $7,332 |
| EBITDA | -$589,022 | -$456,675 | -$248,623 | -$179,747 |
| % Margin | – | -3,943.7% | -702.7% | -611.6% |